Johnson & Johnson Retained Earnings (Accumulated Deficit) 2010-2024 | JNJ

Johnson & Johnson retained earnings (accumulated deficit) from 2010 to 2024. Retained earnings (accumulated deficit) can be defined as profits reinvested in the corporation after dividends have been paid out.
  • Johnson & Johnson retained earnings (accumulated deficit) for the quarter ending September 30, 2024 were $155.179B, a 1.73% increase year-over-year.
  • Johnson & Johnson retained earnings (accumulated deficit) for 2023 were $153.843B, a 19.87% increase from 2022.
  • Johnson & Johnson retained earnings (accumulated deficit) for 2022 were $128.345B, a 4.29% increase from 2021.
  • Johnson & Johnson retained earnings (accumulated deficit) for 2021 were $123.06B, a 8.05% increase from 2020.
Johnson & Johnson Annual Retained Earnings (Accumulated Deficit)
(Millions of US $)
2023 $153,843
2022 $128,345
2021 $123,060
2020 $113,890
2019 $110,659
2018 $106,216
2017 $101,793
2016 $110,551
2015 $103,879
2014 $97,245
2013 $89,493
2012 $85,992
2011 $81,251
2010 $77,773
2009 $70,306
Johnson & Johnson Quarterly Retained Earnings (Accumulated Deficit)
(Millions of US $)
2024-09-30 $155,179
2024-06-30 $155,360
2024-03-31 $153,378
2023-12-31 $153,843
2023-09-30 $152,536
2023-06-30 $129,381
2023-03-31 $124,558
2022-12-31 $128,345
2022-09-30 $127,917
2022-06-30 $126,216
2022-03-31 $124,380
2021-12-31 $123,060
2021-09-30 $121,092
2021-06-30 $120,154
2021-03-31 $116,508
2020-12-31 $113,890
2020-09-30 $114,831
2020-06-30 $113,898
2020-03-31 $112,901
2019-12-31 $110,659
2019-09-30 $109,242
2019-06-30 $109,809
2019-03-31 $106,650
2018-12-31 $106,216
2018-09-30 $107,617
2018-06-30 $106,123
2018-03-31 $104,339
2017-12-31 $101,793
2017-09-30 $114,805
2017-06-30 $113,208
2017-03-31 $111,643
2016-12-31 $110,551
2016-09-30 $108,860
2016-06-30 $106,738
2016-03-31 $104,990
2015-12-31 $103,879
2015-09-30 $102,748
2015-06-30 $101,352
2015-03-31 $98,656
2014-12-31 $97,245
2014-09-30 $96,560
2014-06-30 $93,745
2014-03-31 $91,387
2013-12-31 $89,493
2013-09-30 $87,703
2013-06-30 $89,449
2013-03-31 $87,242
2012-12-31 $85,992
2012-09-30 $84,880
2012-06-30 $83,530
2012-03-31 $83,103
2011-12-31 $81,251
2011-09-30 $82,634
2011-06-30 $80,836
2011-03-31 $79,515
2010-12-31 $77,773
2010-09-30 $77,272
2010-06-30 $75,252
2010-03-31 $73,184
2009-12-31 $70,306
2009-09-30 $69,471
2009-06-30 $67,408
2009-03-31 $65,398
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $368.366B $85.159B
Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $692.744B 71.75
Novo Nordisk (NVO) Denmark $460.555B 33.21
AbbVie (ABBV) United States $294.353B 15.49
Merck (MRK) United States $244.211B 16.23
Novartis AG (NVS) Switzerland $211.084B 14.03
AstraZeneca (AZN) United Kingdom $197.819B 16.83
Pfizer (PFE) United States $142.241B 9.73
Sanofi (SNY) $121.816B 11.03
Innoviva (INVA) United States $1.195B 9.94